May 2009 Volume 6 Number 5
Visit Nature Reviews Cardiology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=14&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Cardiology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=1&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=35&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
*********************************************************************
Nature Reviews Cardiology Impact Factor: 4.743*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
UCSD Clinical and Translation Research Institute and Nature Medicine
present:
Frontiers of Clinical Investigation Symposium
Metabolism 2009: From bench to bedside
October 8-10, 2009
La Jolla, California, USA
The theme for this year's symposium explores innovative approaches to
bridge laboratory investigation to clinical research in metabolism.
Early Bird Deadline: September 8, 2009
Abstract Submission: Deadline: August 21, 2009
For more information visit:
http://links.ealert.nature.com/ctt?kn=118&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
Nature Reviews Cardiology - key scientific developments in cardiology
from a distinguished series.
Ensure your access.
If you are unable to access the articles in this Table of Contents e-alert,
your library may not subscribe to this journal. Our online recommendation
form is a simple way to make your librarian aware that Nature Reviews
Cardiology is valuable to your research.
Recommend now at
http://links.ealert.nature.com/ctt?kn=3&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Cardiomyopathies: EAM-guided biopsy reveals cause of ventricular arrhythmias
p323 | doi:10.1038/nrcardio.2009.42
http://links.ealert.nature.com/ctt?kn=7&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Pharmacogenetics: Optimizing warfarin therapy
p324 | doi:10.1038/nrcardio.2009.39
http://links.ealert.nature.com/ctt?kn=62&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
CRT reduces hospitalization rates
p324 | doi:10.1038/nrcardio.2009.41
http://links.ealert.nature.com/ctt?kn=94&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Device therapy: Antibiotics prevent cardiac-device-related infections
p325 | doi:10.1038/nrcardio.2009.37
http://links.ealert.nature.com/ctt?kn=39&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Angina and coronary artery disease: Life expectancy after CABG
p325 | doi:10.1038/nrcardio.2009.38
http://links.ealert.nature.com/ctt?kn=112&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Reducing Radiation in CT Angiography
p325 | doi:10.1038/nrcardio.2009.40
http://links.ealert.nature.com/ctt?kn=49&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Is dronedarone a new option for AF patients?
p326 | doi:10.1038/nrcardio.2009.36
http://links.ealert.nature.com/ctt?kn=113&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Acute coronary syndromes: Fasting blood glucose in ACS patients
p326 | doi:10.1038/nrcardio.2009.43
http://links.ealert.nature.com/ctt?kn=16&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Correction: JUPITER strikes earth
p326 | doi:10.1038/nrcardio.2009.54
http://links.ealert.nature.com/ctt?kn=21&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Disease Prevention: The moving target of global cardiovascular health
Rajesh Vedanthan and Valentin Fuster
p327 | doi:10.1038/nrcardio.2009.48
The cardiovascular community has witnessed an important transition over
the past two decades-from awareness of the global nature of the
cardiovascular disease epidemic, to identification of interventions to
control it, and now to a resolution that global action is urgently required.
http://links.ealert.nature.com/ctt?kn=77&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Angina: Ivabradine for treatment of stable angina pectoris
Ranil de Silva and Kim M. Fox
p329 | doi:10.1038/nrcardio.2009.47
The ASSOCIATE study investigators have reported that the If current
inhibitor, ivabradine, is safe, improves exercise performance, and
delays the development of ischemia in patients with chronic stable angina
being treated with atenolol. Ivabradine should be considered in the
medical management of symptom-limited patients with angina, when heart
rate is suboptimally controlled.
http://links.ealert.nature.com/ctt?kn=91&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Valve Disease: Asymptomatic mitral regurgitation: does surgery save lives?
David H. Adams and Anelechi C. Anyanwu
p330 | doi:10.1038/nrcardio.2009.50
Management of asymptomatic patients with severe mitral valve regurgitation
is controversial-conservative surveillance and early mitral valve repair
have both been advocated as reasonable approaches on the basis of
divergent data. A new study by Kang et al. fuels this debate. However,
careful assessment of the existing literature can provide insight into
the optimal care of this population of patients.
http://links.ealert.nature.com/ctt?kn=30&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Atrial Fibrillation: A4 study: proof of concept?
A. John Camm and Irina Savelieva
p332 | doi:10.1038/nrcardio.2009.49
The A4 and other similar (small) studies strongly support the launch of
major trials of left atrial catheter ablation for the maintenance of
sinus rhythm, reduction of cardiovascular hospitalizations and improved
survival in patients with symptomatic recurrent atrial fibrillation.
Will pharmacological therapies continue to have an important place in
the management of atrial fibrillation?
http://links.ealert.nature.com/ctt?kn=107&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Antiplatelet therapy: Personalized medicine for clopidogrel resistance?
Jean-Sebastien Hulot and Valentin Fuster
p334 | doi:10.1038/nrcardio.2009.28
The benefits of clopidogrel in the treatment and prevention of coronary
artery disease vary among patients. Studies have identified predictive
markers of poor response to clopidogrel that might allow risk stratification
of patients. Are we ready to enter the age of personalized medicine?
http://links.ealert.nature.com/ctt?kn=110&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Sodium channel mutations and arrhythmias
Yanfei Ruan, Nian Liu and Silvia G. Priori
p337 | doi:10.1038/nrcardio.2009.44
This Review describes the current understanding of the molecular mechanism
of inherited arrhythmias. Focus is placed on arrhythmia-causing mutations
in the genes encoding the [alpha] subunit of the cardiac sodium channel
(SCN5A) but arrhythmia-causing mutations in the genes encoding the [beta]
subunit and other proteins in the associated macromolecular complex are
also discussed.
Abstract: http://links.ealert.nature.com/ctt?kn=71&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=82&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical
implications
Praneet Kumar, Gary S. Francis and W. H. Wilson Tang
p349 | doi:10.1038/nrcardio.2009.32
The use of phosphodiesterase 5 (PDE5) inhibitors for the treatment of
heart failure is an emerging field of research. The authors of this timely
Review examine the available basic and clinical data on PDE5 inhibition
in the context of heart failure, providing a mechanistic overview and
discussing the potential clinical implications of this therapy.
Abstract: http://links.ealert.nature.com/ctt?kn=86&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=102&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Prevention of venous thromboembolism in medical patients and outpatients
Gregg J. Stashenko and Victor F. Tapson
p356 | doi:10.1038/nrcardio.2009.33
In this comprehensive Review, Drs Stashenko and Tapson examine the
literature on the use of venous thromboembolism prophylaxis in
hospitalized medical patients, and evaluate the available data for the
outpatient setting. The authors also discuss the potential strategies
for improving venous thromboembolism prophylaxis rates in these groups
of patients.
Abstract: http://links.ealert.nature.com/ctt?kn=108&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=109&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet
drugs-fact or artifact?
Diana A. Gorog, Joseph M. Sweeny and Valentin Fuster
Published online: 14 April 2009
p365 | doi:10.1038/nrcardio.2009.13
In the second part of their Review on resistance to antiplatelet medication,
the authors discuss the various laboratory tests of platelet function and
highlight the limitations of these methods for determining the true
thrombotic status of the patient.
Abstract: http://links.ealert.nature.com/ctt?kn=75&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=13&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
----------------------
CASE STUDIES
----------------------
First case of stenting of a vulnerable plaque in the SECRITT I trial-the
dawn of a new era?
Steve Ramcharitar, Nieves Gonzalo, Robert Jan van Geuns, Hector M.
Garcia-Garcia, Joanna J. Wykrzykowska, Jurgen M. R. Ligthart, Evelyn Regar
and Patrick W. Serruys
p374 | doi:10.1038/nrcardio.2009.34
Ramcharitar et al. describe the first case treated in the SECRITT I
trial. The 63-year-old man presented with class II anginal symptoms and
was diagnosed as having a culprit lesion in the left circumflex artery
and a vulnerable plaque in the left anterior descending artery. The
vulnerable plaque was treated with a self-expanding stent tailored to
shield this type of plaque.
Abstract: http://links.ealert.nature.com/ctt?kn=115&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Ruptured sinus of Valsalva aneurysm presenting as ST-elevation myocardial infarction
Alistair C. Lindsay, Balakrishnan Mahesh, Jullien A. Gaer and Miles C. D. Dalby
p379 | doi:10.1038/nrcardio.2009.45
Lindsay et al. present an interesting case of a patient with a ruptured
sinus of Valsalva aneurysm. The authors recommend the early use of imaging
modalities for prompt diagnosis, as anticoagulation therapy might have
detrimental effects on patient outcome. Reparative surgery is safe and
successful in almost all noninfective cases.
Abstract: http://links.ealert.nature.com/ctt?kn=54&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=38&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
AJH Reader's Choice: Higher heart rate may predispose to obesity and
diabetes mellitus: 20-year prospective study in a general population.
Online at
http://links.ealert.nature.com/ctt?kn=34&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
Is a higher bpm a cause, consequence or epiphenomenon in metabolic syndrome?
This study from AJH is available online FREE of charge and re-examines
participants 20 years later for cardiometabolic factors.
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=89&m=32306543&r=MTc2NDI1MzEzNAS2&b=2&j=NDc1NDY5MDcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
